Abstract:Apatinib is a tyrosine kinase inhibitor which selectively inhibits VEGFR-2 and also represents mild inhibition to PDGFR, c-Kit and c-src. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis and tumor cell proliferation. Previous clinical trials have demonstrated its obvious antitumor activity in various cancer type. Thus we designed this phase II, open-label, single-armed, prospective study (NCT02515435) to investigate the efficacy and safety of apatinib for heavily treated, advanced non-squamous NSCLC patients who are not applicable to current standardized therapy or other clinical trials. We prospectively enrolled 40 patients with previously heavily treated advanced non-squamous NSCLC. All patients received apatinib with a dose of 500mg, q.d., p.o. Efficiency was evaluated initially 4 weeks later and then every 8 weeks until disease progression, death, or unacceptable toxicity. The primary end point of this study was overall response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS). Forty patients were enrolled in the study with a median age of 61. 15% of patients received apatinib as second-line therapy, 40% of patients received apatinib as third-line therapy, and 60% as forth-line to twelfth-line therapy. Nine patients were found with activated EGFR mutation. Among all the enrolled patients, 38 patients had clinical evaluation and the other 2 received treatment of apatinib less than one month. Within 33 patients who had available image efficiency, 6 were identified as PR,17 SD and 10 PD, no CR was observed. The ORR was 18.18 %, the DCR was 69.69%. The ORR for patients with EGFR mutation positive and negative were 25% and 16% separately. The median PFS was 3.22 months (95% CI, 2.20-4.17 months). Among them, 6 patients received the treatment of apatinib more than five months. The 6-month OS rate was 76.98% (95% CI, 61.68%-92.27%), the 12-month OS rate was 57.48% (95% CI, 28.75%-86.20%). Common treatment-related adverse events were proteinuria (25%), hypertension (17.5%), and hand-foot-skin reaction (HFSR)(27.5%). Severe adverse events included grade 3 hypertension (5%), HFSR (5%), and thrombocytopenia (5%), no grade 4 or 5 adverse events were observed. No un-expected adverse events were found. Apatinib as a monotherapy had a promising overall response together with an acceptable side effect in patients with previously heavily treated advanced non-squamous NSCLC. A phase III study comparing apatinib monotherapy with placebo as 3rd/4th setting in advanced non-squamous NSCLC is ongoing to further evaluated the efficacy of apatinib (NCT02332512).

Combination Therapy of Apatinib with Icotinib for Primary Acquired Icotinib Resistance in Patients with Advanced Pulmonary Adenocarcinoma with EGFR Mutation.

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.

Apatinib with First-Generation EGFR-TKIs As Second-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer with Acquired Resistance: a Retrospective Case Series Analysis

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Apatinib Enhances Antitumour Activity of EGFR-TKIs in Non-Small Cell Lung Cancer with EGFR-TKI Resistance

Dual Blockade of EGFR and VEGFR Pathways: Results from a Pilot Study Evaluating Apatinib Plus Gefitinib As a First‐line Treatment for Advanced EGFR‐mutant Non‐small Cell Lung Cancer

Potential Mechanism of Primary Resistance to Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring Uncommon Mutant Epidermal Growth Factor Receptor: A Multi-Center Study

Pemetrexed-carboplatin with Intercalated Icotinib in the Treatment of Patient with Advanced EGFR Wild-Type Lung Adenocarcinoma

P3.13-21 Apatinib Plus Icotinib As First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: an Exploratory Study

1805P Apatinib Combined with Irinotecan in the Treatment of Small Cell Lung Cancer: A Phase II, Single-Arm, Prospective Study

Sequential Treatment of Icotinib after First-Line Pemetrexed in Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status.

Combination of icotinib and wogonin induces apoptosis and autophagy to overcome acquired resistance in lung cancer harbouring EGFR T 790 M mutation

Real‐world Efficacy and Potential Mechanism of Resistance of Icotinib in Asian Advanced Non‐small Cell Lung Cancer with EGFR Uncommon Mutations: A Multi‐center Study